Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
Roxana Dronca MD
Roxana S. Dronca MD Advisory Board
Oliver Sartor MD
Oliver Sartor MD Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · May 05, 2016

Cetuximab ± Irinotecan in Refractory Metastatic Colorectal Cancer Harboring G13D KRAS

Journal of Clinical Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Journal of Clinical Oncology
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study
J. Clin. Oncol 2016 Apr 25;[EPub Ahead of Print], E Segelov, S Thavaneswaran, PM Waring, J Desai, KP Robledo, VJ Gebski, E Elez, LM Nott, CS Karapetis, S Lunke, LA Chantrill, N Pavlakis, M Khasraw, C Underhill, F Ciardiello, M Jefford, H Wasan, A Haydon, TJ Price, G van Hazel, K Wilson, J Simes, JD Shapiro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated